Transluminal Technologies is ready to take on the European market with CE Mark approval for its flagship Velox CD vascular closure devices.
EndoShape is in the process of raising $6.8 million in the latest reported funding round for the minimally invasive vessel occlusion devices maker.
Admedus won 510(k) clearance from the U.S. FDA for its CardioCel cardiovascular scaffold.
Perth, Australia and Minneapolis, Minn.-based Admedus is developing implantable regenerative technologies. CardioCel, the company’s 1st product, is a pure collagen, bio-compatible regenerative tissue scaffold.
Sapheon secured approval from Health Canada for its VenaSeal Sapheon closure system, used in the treatment of varicose veins.
Morrisville, N.C.-based Sapheon develops treatments for vascular disease, its flagship product being the VenaSeal, a medical adhesive which seals blood vessels using a special glue. The company is currently working towards getting pre-market approval from the U.S. FDA.
Scion Biomedical sued board member and interim chief strategy and operating officer Allison London Brown, accusing her of poaching trade secrets for her startup medical device company, Aegis Women’s Health Technologies.
California medical device company Cardiva Medical won FDA approval for its Vascade extravascular closure device, the company announced this week.
The premarket approval was granted based on evidence from Cardiva’s 420-patient clinical trial, which demonstrated that Vascade beat the gold standard of manual compression for vascular closure patients undergoing percutaneous procedures via the femoral artery, according to a press release.